Abstract:The nano‐sized extracellular matrix is conjugated with doxorubicin using cis‐aconitic anhydride to prepare extracellular matrix‐drug conjugates, endowing them with acid‐sensitive drug release properties. These conjugates can be internalized into tumor cells via hyaluronic acid receptors and integrins, enhancing tumor site accumulation and antitumor efficacy while reducing organ toxicity of doxorubicin. The extracellular matrix (ECM) engages in regulatory interactions with cell surface receptors through its constituent proteins and polysaccharides. Therefore, nano‐sized extracellular matrix conjugated with doxorubicin (DOX) is utilized to produce extracellular matrix‐drug conjugates (ECM‐DOX) tailored for targeted delivery to cancer cells. The ECM‐DOX nanoparticles exhibit rod‐like morphology, boasting a commendable drug loading capacity of 4.58%, coupled with acid‐sensitive drug release characteristics. Notably, ECM‐DOX nanoparticles enhance the uptake by tumor cells and possess the ability to penetrate endothelial cells and infiltrate tumor multicellular spheroids. Mechanistic insights reveal that the internalization of ECM‐DOX nanoparticle is facilitated through clathrin‐mediated endocytosis and macropinocytosis, intricately involving hyaluronic acid receptors and integrins. Pharmacokinetic assessments unveil a prolonged blood half‐life of ECM‐DOX nanoparticles at 3.65 h, a substantial improvement over the 1.09 h observed for free DOX. A sustained accumulation effect of ECM‐DOX nanoparticles at tumor sites, with drug levels in tumor tissues surpassing those of free DOX by several‐fold. The profound therapeutic impact of ECM‐DOX nanoparticles is evident in their notable inhibition of tumor growth, extension of median survival time in animals, and significant reduction in DOX‐induced cardiotoxicity. The ECM platform emerges as a promising carrier for avant‐garde nanomedicines in the realm of cancer treatment.

Combretastatin A4 Nanodrug‐Induced MMP9 Amplification Boosts Tumor‐Selective Release of Doxorubicin Prodrug

Matrix Metalloproteinase-Sensitive Size-Shrinkable Nanoparticles for Deep Tumor Penetration and Ph Triggered Doxorubicin Release.

A Ph‐responsive Nanoparticle Delivery System Containing Dihydralazine and Doxorubicin‐based Prodrug for Enhancing Antitumor Efficacy

Polymer-lipid Hybrid Nanoparticles Synchronize Pharmacokinetics of Co-Encapsulated Doxorubicin-Mitomycin C and Enable Their Spatiotemporal Co-Delivery and Local Bioavailability in Breast Tumor.

Drug Resistance Reversal By Combretastatin-A4 Phosphate Loaded With Doxorubicin In Polymersomes Independent Of Angiogenesis Effect

Glycyrrhetinic acid remodels the tumor microenvironment and synergizes with doxorubicin for breast cancer treatment in a murine model

Tumor-Cell-Surface Adherable Peptide-Drug Conjugate Prodrug Nanoparticles Inhibit Tumor Metastasis and Augment Treatment Efficacy.

MT1‐MMP‐Activated Liposomes to Improve Tumor Blood Perfusion and Drug Delivery for Enhanced Pancreatic Cancer Therapy

Precise Engineering of Prodrug Cocktails into Single Polymeric Nanoparticles for Combination Cancer Therapy: Extended and Sequentially Controllable Drug Release

Enzyme‐Activated Prodrug‐Based Smart Liposomes Specifically Enhance Tumor Hemoperfusion with Efficient Drug Delivery to Pancreatic Cancer Cells and Stellate Cells

A Dual Strategy to Improve the Penetration and Treatment of Breast Cancer by Combining Shrinking Nanoparticles with Collagen Depletion by Losartan

Matrix Metalloproteinase-2-Induced Morphologic Transformation of Self-Assembled Peptide Nanocarriers Inhibits Tumor Growth and Metastasis

Enhanced Drug Delivery by Nanoscale Integration of a Nitric Oxide Donor To Induce Tumor Collagen Depletion

Tumor-Selective Cascade-Amplified Dual-Prodrugs Activation for Synergistic Oxidation-Chemotherapy

Breast cancer-targeted therapy and doxorubicin multidrug resistance are reversed via macrophage membrane-camouflaged liposomes

Enhanced Tumor Site Accumulation and Therapeutic Efficacy of Extracellular Matrix‐Drug Conjugates Targeting Tumor Cells

Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity

Collagen-anchored Cascade Nanoreactors with Prolonged Intratumoral Retention for Combined Cancer Starvation and Chemotherapy

Co-delivery of Doxorubicin and Arsenite with Reduction and Ph Dual-Sensitive Vesicle for Synergistic Cancer Therapy

Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies.

Co-delivery of Plinabulin and Tirapazamine boosts anti-tumor efficacy by simultaneously destroying tumor blood vessels and killing tumor cells